CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BEZH2expressionPredictiveSupportsSensitivity/ResponseDiffuse Large B-cell Lymphoma Germinal Center B-cell TypeTazemetostatMunakata et al., 2021
BNOTKIT D816VPredictiveSupportsSensitivity/ResponseSystemic MastocytosisImatinib MesylateVega-Ruiz et al., 2009
Av::NTRK2FusionPredictiveSupportsSensitivity/ResponseSolid TumorEntrectinibDoebele et al., 2020
CMN1::ZFTAFusionDiagnosticSupportsPositiveSupratentorial Ependymoma, ZFTA Fusion–positiveTauziède-Espariat et al., 2021
CQKI::NTRK2FusionOncogenicSupportsOncogenicityLow Grade GliomaSolomon et al., 2020
CQKI::NTRK2FusionOncogenicSupportsOncogenicityPolymorphous Low Grade Neuroepithelial Tumour Of The YoungIda et al., 2021
CQKI::NTRK2FusionOncogenicSupportsOncogenicityPilocytic AstrocytomaJones et al., 2013
CNTRK3::SCAPERFusionOncogenicSupportsOncogenicityPigmented Epithelioid MelanocytomaFriedman et al., 2020
CP2RY8::CRLF2FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeRoberts et al., 2014
CERBB2D769YPredictiveSupportsSensitivity/ResponsePeritoneal CarcinomaAfatinibBedard et al., 2022
CERBB2V777LPredictiveSupportsSensitivity/ResponseBreast CancerAfatinibBedard et al., 2022
Cv::MITFFusionDiagnosticSupportsPositiveRenal Cell Carcinoma With MiT TranslocationsBakouny et al., 2022
CKANK1::NTRK2FusionPredictiveSupportsSensitivity/ResponseGanglioneuroblastomaEntrectinibDesai et al., 2022
CGOPC::ROS1FusionPredictiveSupportsSensitivity/ResponseLow Grade GliomaEntrectinibDesai et al., 2022
CTPM3::NTRK1FusionPredictiveSupportsSensitivity/ResponseMyofibromaEntrectinibDesai et al., 2022
CTFG::ROS1FusionPredictiveSupportsSensitivity/ResponseInflammatory Myofibroblastic TumorEntrectinibDesai et al., 2022
CYAP1::FAM118BFusionDiagnosticSupportsPositiveSupratentorial Ependymoma, YAP1 Fusion–positiveWang et al., 2021
CBCR::NTRK2FusionPredictiveSupportsSensitivity/ResponseBrain Glioblastoma MultiformeEntrectinibGrogan et al., 2022
CEGFR::USP42FusionOncogenicSupportsOncogenicityLung AdenocarcinomaGuan et al., 2019
BTMBHighPredictiveSupportsSensitivity/ResponseColorectal CancerPembrolizumabSchrock et al., 2019
CKRASG12VPredictiveSupportsResistanceColorectal CancerPanitumumabAmado et al., 2008
CKRASG12DPredictiveSupportsResistanceColorectal CancerPanitumumabAmado et al., 2008
DKRASG12DPredictiveSupportsResistanceMultiple MyelomaMelphalanRowley et al., 2002
DKRASG12CPredictiveSupportsResistanceMultiple MyelomaMelphalanRowley et al., 2002
CKRASG12RPredictiveSupportsResistanceColorectal CancerPanitumumabAmado et al., 2008
CKRASG12SPredictiveSupportsResistanceColorectal CancerPanitumumabAmado et al., 2008
CTP53R273LPredictiveSupportsResistanceOvarian CancerCarboplatin,CisplatinReles et al., 2001
CTP53R175HPredictiveSupportsSensitivity/ResponseStomach CarcinomaEAP ProtocolBataille et al., 2003
BBRAFV600KPredictiveSupportsSensitivity/ResponseMelanomaDabrafenibLong et al., 2011
CEGFRG719APredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibDouillard et al., 2010
CTP53Y234CPredictiveSupportsResistanceOvarian CancerCarboplatin,CisplatinReles et al., 2001
CTP53R282LPredictiveSupportsSensitivity/ResponseStomach CarcinomaEAP ProtocolBataille et al., 2003
CTP53R213PPredictiveSupportsSensitivity/ResponseStomach CarcinomaEAP ProtocolBataille et al., 2003
CBRCA1Q1467*PredictiveSupportsSensitivity/ResponseOvarian CancerRucaparibSwisher et al., 2017
CBRCA2M1RPredictiveSupportsSensitivity/ResponseOvarian CancerRucaparibSwisher et al., 2017
CBRCA2M1IPredictiveSupportsSensitivity/ResponseOvarian CancerRucaparibSwisher et al., 2017
CBRCA2V159MPredictiveSupportsSensitivity/ResponseOvarian CancerRucaparibSwisher et al., 2017
CBRCA2V211LPredictiveSupportsSensitivity/ResponseOvarian CancerRucaparibSwisher et al., 2017
CBRCA2V211IPredictiveSupportsSensitivity/ResponseOvarian CancerRucaparibSwisher et al., 2017
CBRCA2R2336PPredictiveSupportsSensitivity/ResponseOvarian CancerRucaparibSwisher et al., 2017
BNRASG12DPredictiveSupportsResistanceColorectal CancerCetuximabKaczirek et al., 2015
DHRASG13DPredictiveSupportsResistanceColorectal CancerCetuximabBoidot et al., 2016
CKRASQ61HPredictiveSupportsResistanceColorectal CancerCetuximabMisale et al., 2012
DKRASG13DPredictiveSupportsResistanceColorectal CancerCetuximabMisale et al., 2012
BKRASG13DPredictiveSupportsResistanceColorectal CancerCetuximabKaczirek et al., 2015
CFLT3D835VPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaSunitinibFiedler et al., 2005
CKITK642EPredictiveSupportsSensitivity/ResponseMelanomaDasatinibKluger et al., 2011
DEGFRG719SPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinibKancha et al., 2009
DEGFRV742APredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinibKancha et al., 2009
DEGFRL747_P753delinsSPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinibKancha et al., 2009
Page 95 of 96
PreviousNext